The rapid development and emergence into the marketplace of therapeutic and diagnostic biotechnology products pose a considerable challenge to pharmacists, particularly in light of economic strictures wrought by changes in the health care field. At the same time, the pharmacy profession is moving to a position of greater involvement and responsibility in the clinical management of drug therapy. These changes mandate that pharmacists become strategic thinkers, capable of designing and implementing plans that can integrate biotechnology products into their institutions' practices in a way that both enhances patient care and maintains or promotes financial stability. A strategic plan model incorporating the components of environmental scanning and strategy formulation, implementation, and analysis can be applied to the recombinant colony-stimulating factors.